4.6 Article

Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States

期刊

GENETICS IN MEDICINE
卷 24, 期 5, 页码 1017-1026

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.gim.2020.01.017

关键词

Colorectal cancer; Cost-effectiveness analysis; Lynch syndrome; Population screening

向作者/读者索取更多资源

This study evaluated the cost-effectiveness of population-wide genomic screening for Lynch syndrome (LS) in an unselected US population and found that LS screening may be cost-effective for younger patient populations. However, further reductions in testing costs and the inclusion of LS testing in broader screening panels are needed to achieve high cost-effectiveness.
Purpose: Genomic screening for Lynch syndrome (LS) could prevent colorectal cancer (CRC) by identifying high-risk patients and instituting intensive CRC screening. We estimated the cost-effectiveness of a population-wide LS genomic screening vs family history-based screening alone in an unselected US population. Methods: We developed a decision-analytic Markov model including health states for precancer, stage-specific CRC, and death and assumed an inexpensive test cost of $200. We conducted sensitivity and threshold analyses to evaluate model uncertainty. Results: Screening unselected 30-year-olds for LS variants resulted in 48 (95% credible range [CR] = 35-63) fewer overall CRC cases per 100,000 screened individuals, leading to 187 quality-adjusted life-years (QALYs; 95% CR = 123-260) gained at an incremental cost of $24.6 million (95% CR = $20.3 million-$29.1 million). The incremental cost-effectiveness ratio was $132,200, with an 8% and 71% probability of being cost-effective at $100,000 and $150,000 per QALY willingness-to-pay thresholds, respectively. Conclusion: Population LS screening may be cost-effective in younger patient populations under a $150,000 willingness-to-pay per QALY threshold and with a relatively inexpensive test cost. Further reductions in testing costs and/or the inclusion of LS testing within a broader multiplex screening panel are needed for screening to become highly cost-effective. (C) 2022 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据